ORIGINAL: Cap Mandrake
Here is the likely source of confusion. The CDC published an update on March 30 which clarified new information on "pre-symptomatic" and "asymptomatic". The former means individuals known to have the virus in their respiratory tract or gut with no symptoms YET.
The latter are those individuals proven to have the virus but NEVER have symptoms. The presence and size of the latter group has recently been better delineated. The Governor said the state medical director told him it was a "game changer". That is largely true. If there is a large reservoir of persistently infectious yet entirely asymptomatic patients the damn thing is MORE dangerous.
Of course, being a science guy I figured this out myself in January when I saw the Chinese data which seemed to largely skip children (who probably harbor more asymptomatic cases). The Governor is not a science guy and he had to wait for his advisers to clarify it.
A question for you: I read something that the TB vaccine give something like an 80% protection against this new corona virus, is that now given to children?
Summary: VPM1002, a vaccine candidate based on the tuberculosis BCG vaccine, may be effective in protecting against COVID-19. Previous studies in mice have shown the BCG vaccine is effective at protecting against several respiratory viral infections. If effective against coronavirus, researchers hope the vaccine can bridge the time gap until a specific SARS-CoV-2 vaccine is available.
Source: Max Planck Institute
The course of the corona pandemic will strongly depend on how quickly medications or vaccines against the SARS co-virus 2 can be developed. In at least one Phase III study, researchers want to investigate whether the vaccine candidate VPM1002, originally developed against tuberculosis by scientists at the Max Planck Institute for Infection Biology, is also effective against infection with SARS-CoV-2. The large-scale study is to be carried out at several hospitals in Germany and will include older people and health care workers. Both groups are particularly at risk of the disease. VPM1002 could thus help bridge the time until a vaccine specifically effective against SARS co-virus 2 is available.
VPM1002 is based on a vaccine called BCG, which was developed at the beginning of the 20th century. Studies on mice show that the BCG vaccine can protect not only against tuberculosis but also against viral infections of the respiratory tract. Accordingly, mice suffering from influenza have fewer influenza A viruses in their blood if they had previously been vaccinated with BCG. The animals thus showed less damage to the lungs.
According to further studies, vaccination with BCG also increases the animals’ resistance to other viruses (e.g. herpes type 1 and 2). Apparently, a vaccination with BCG also activates the immune system against a viral infection. In this way, the vaccine reduces the risk of severe disease progression and thus lowers the death rate.
Some of you may already be familiar with the BGC, short for bacillus Calmette-Guerin, which is supposed to provide defense against tuberculosis. Not gets this vaccine since tuberculosis isn’t as widespread as it used to be, especially in developed countries. The vaccine isn’t just used against tuberculosis, as it has become conventional immunotherapy for early-stage bladder cancer as well. And it’s thanks to its effects on the immunity that researchers are considering it as a potential therapy for COVID-19.
The idea is that an immune boost could raise the body’s defenses against pathogens like the new SARS-CoV-2 virus, and potentially defeat the infection faster.
The Australian government, in partnership with the World Health Organization (WHO), kicked off a six-month trial in Melbourne at the Murdoch Children’s Research Institute. Some 4,000 healthcare workers are included in the study that kicked of Monday, Bloomberg reported. They’ll be divided into two groups, one vaccinated against the flu and TB and the other just against the flu.
A research group at the University of Melbourne is setting up a BCG study among health care workers using the exact same protocol. Another research group at the University of Exeter will do a similar study in the elderly. And a team at the Max Planck Institute for Infection Biology last week announced that—inspired by Netea’s work—it will embark on a similar trial in elderly people and health workers with VPM1002, a genetically modified version of BCG that has not yet been approved for use against TB.
Eleanor Fish, an immunologist at the of the University of Toronto, says the vaccine probably won’t eliminate infections with the new coronavirus completely, but is likely to dampen its impact on individuals. Fish says she’d take the vaccine herself if she could get a hold of it, and even wonders whether it’s ethical to withhold its potential benefits from trial subjects in the placebo arm.
< Message edited by RangerJoe -- 4/5/2020 10:45:12 PM >
Seek peace but keep your gun handy.
I'm not a complete idiot, some parts are missing!
“Illegitemus non carborundum est (“Don’t let the bastards grind you down”).”
― Julia Child